Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Fase I/II-studie naar antisense oligonucleotide tofersen bij SOD1-ALS
sep 2020 | Neuro-musculair